Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-06-28
2011-06-28
Shiao, Rei-tsang (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S517000
Reexamination Certificate
active
07968590
ABSTRACT:
IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a Kdof less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
REFERENCES:
patent: 3832253 (1974-08-01), DiPalma et al.
patent: 3854480 (1974-12-01), Zaffaroni
patent: 4278793 (1981-07-01), Durckheimer et al.
patent: 4452775 (1984-06-01), Kent
patent: 4667014 (1987-05-01), Nestor, Jr. et al.
patent: 4748034 (1988-05-01), DeRham
patent: 5075109 (1991-12-01), Tice et al.
patent: 5239660 (1993-08-01), Ooi
patent: 5660811 (1997-08-01), Mills
patent: 5766572 (1998-06-01), Hasegawa et al.
patent: 6110691 (2000-08-01), Wang et al.
patent: 6133437 (2000-10-01), Korneluk et al.
patent: 6187557 (2001-02-01), Rothe et al.
patent: 6338835 (2002-01-01), Shochat et al.
patent: 6608026 (2003-08-01), Wang
patent: 6911426 (2005-06-01), Reed et al.
patent: 6992063 (2006-01-01), Shi
patent: 7217688 (2007-05-01), Reed et al.
patent: 7244851 (2007-07-01), Cohen et al.
patent: 7309792 (2007-12-01), Harran et al.
patent: 7456209 (2008-11-01), Condon et al.
patent: 7579320 (2009-08-01), Boudreault et al.
patent: 7718600 (2010-05-01), McLendon et al.
patent: 7807699 (2010-10-01), Hanson et al.
patent: 2002/0132786 (2002-09-01), Alnemri et al.
patent: 2002/0160975 (2002-10-01), Alnemri
patent: 2002/0177557 (2002-11-01), Shi
patent: 2004/0054148 (2004-03-01), Alnemri
patent: 2005/0197403 (2005-09-01), Harran et al.
patent: 2005/0234042 (2005-10-01), Palermo et al.
patent: 2005/0261203 (2005-11-01), Cohen et al.
patent: 2006/0014700 (2006-01-01), Cohen et al.
patent: 2006/0025347 (2006-02-01), Condon et al.
patent: 2006/0052311 (2006-03-01), Sharma et al.
patent: 2006/0128632 (2006-06-01), Sharma et al.
patent: 2006/0167066 (2006-07-01), Cohen et al.
patent: 2006/0194741 (2006-08-01), Condon et al.
patent: 2006/0258581 (2006-11-01), Reed et al.
patent: 2006/0264379 (2006-11-01), Jarvis et al.
patent: 2007/0003535 (2007-01-01), Reed et al.
patent: 2007/0042428 (2007-02-01), Springs et al.
patent: 2007/0093428 (2007-04-01), Laurent
patent: 2007/0093429 (2007-04-01), Laurent et al.
patent: 2009/0005411 (2009-01-01), Jensen et al.
patent: 2009/0104151 (2009-04-01), Hanson et al.
patent: 2009/0123480 (2009-05-01), Wang et al.
patent: 2009/0142334 (2009-06-01), Korneluk et al.
patent: 2009/0192140 (2009-07-01), Laurent et al.
patent: 2010/0130539 (2010-05-01), Koehler
patent: WO 99/15657 (1999-04-01), None
patent: WO 02/16418 (2002-02-01), None
patent: WO 02/26775 (2002-04-01), None
patent: WO 02/30959 (2002-04-01), None
patent: WO 02/096930 (2002-12-01), None
patent: WO 02096930 (2002-12-01), None
patent: WO 03/018014 (2003-03-01), None
patent: 2004005248 (2004-01-01), None
patent: WO 2004/007529 (2004-01-01), None
patent: 2004072105 (2004-08-01), None
patent: 2005069888 (2005-08-01), None
patent: 2005069894 (2005-08-01), None
patent: 2005078989 (2005-08-01), None
patent: WO 2005074989 (2005-08-01), None
patent: 2005084317 (2005-09-01), None
patent: 2005094818 (2005-10-01), None
patent: 2005097791 (2005-10-01), None
patent: 2006010118 (2006-01-01), None
patent: 2006014361 (2006-02-01), None
patent: 2006017295 (2006-02-01), None
patent: 2006020060 (2006-02-01), None
patent: 2006069063 (2006-06-01), None
patent: 2006091972 (2006-08-01), None
patent: 2006122408 (2006-11-01), None
patent: 2006128455 (2006-12-01), None
patent: 2006133147 (2006-12-01), None
patent: 2007101347 (2007-09-01), None
patent: 2007130626 (2007-11-01), None
patent: WO 2008016893 (2008-02-01), None
patent: WO 2008057172 (2008-05-01), None
patent: 2007106192 (2008-09-01), None
patent: WO 2008134679 (2008-11-01), None
McLendon et al., 2010, CAS: 152:568466.
Macor et al., The Synthesis of a Conformationally Restricted Analog of the Anti-Migraine Drug Sumatriptan, 1992, Tetrahedron Lett. 33(52):8011-8014.
Chawla-Sarkar, Preferential Induction of Apoptosis by Interferon 9IFN)-β Compared with IFN-α2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines, 2001, Clin. Can. Res. 7:1821-1831.
Sun et al., Structure-based Design of Potent, Conformationally Constrained Smac Mimetics, 2004, J. Am. Chem. Soc. 126:16686-16687.
Park et al., Non-peptide small molecule inhibitors of XIAP, 2004, Bioorganic & Med. Chem. Lett. 15:771-775.
Lang's Handbook of Chemistry, Dean ed., Table 7-2, 1985.
Fulda et al., Smac agonists sensitize for Apo2L/TRAIL—or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo, 2002, Nat. Med. 8(8):808-815.
Wu et al., Structural Analysis of a Functional DIAP1 Fragment Bound to Grim and Hid Peptides, 2001, Mol. Cell 8:95-104.
Kohli et al., SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells, 2004, PNAS 101(48):16987-16902.
Nikolovska-Coleska et al., Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization, 2004, Anal. Biochem. 332:261-273.
Hansen et al., Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, 1989, J. Immunol. Methods 119:203-210.
Deveraux et al., IAP family proteins-suppressors of apoptosis, 1999, Genes & Devel. 13:239-252.
Kasof et al., Livin, a novel inhibitor of apoptosis protein family member, 2001, J. Biol. Chem. 276(5):3238-3246.
Vucic et al., ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas, 2000, Curr. Biol. 10:1359-1366.
Ashhab et al., Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern, 2001, FEBS Lett. 495:56-60.
Du et al., Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition, 2000, Cell 102:33-42.
Verhagen et al., Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins, 2000, Cell 102:42-53.
Vucic et al., Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP, 2005, Biochem. J. 385(1):11-20.
Li et al., A small molecule Smac mimic potentiates TRAIL- and TNFα-medicated cell death, Science, vol. 305 (2004), pp. 1471-1474.
Oost et al., Discovery of Potent Antagonists of the Antiapoptotic Protein XIAP for the Treatment of Cancer, 2004, J. Med. Chem. 47:4417-4426.
Chai et al., Structural and biochemical basis of apoptotic activation by Smac/DIABLO, 2000, Nature 406:855-862.
Ambrosini et al., Induction of Apoptosis and Inhibition of Cell Proliferation by survivin Gene Targeting, 1998, J. Biol. Chem. 273(18):11177-11182.
Ripka et al., Peptidomimetic design, 1998, Curr. Op. Chem. Biol. 2:441-452.
Hruby et al., Synthesis of oligopeptide and peptidomimetic libraries, 1997, Curr. Op. Chem. Biol. 1:114-119.
Hruby et al., Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads, 2000, Curr. Med. Chem. 9:945-970.
Wyllie et al., Cell Death: the significance of apoptosis, 1980, Int. Rev. Cytol. 68:251-306.
Wyllie, Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation, 1981, Nature 284:555-556.
Hay, Understanding IAP function and regulation: a view from Drosophila, 2000, Cell Death and Diff. 7:1045-1056.
Chan et al., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, 2000, Oxford University Press (TOC).
Boxrud et al., Streptokinase Binds to Human Plasmin with High Affinity, Perturbs the Plasmin Active Site, and Induces Expression of a Substrate Recognition Exosite for Plasminogen, 2000, J. Biol. Chem. 275(19):14579-14589.
Owenius et al., Properties of Spin and Fluorescent Labels at a Receptor-Ligand Interface, 1999, Biophys. J. 77:2237-2250.
Hiratsuka, ATP-induced Opposite Changes in the Local Environments around Cys697(SH2) and Cys707(
Condon Stephen M.
Deng Yijun
LaPorte Matthew G.
Rippin Susan R.
Banner & Witcoff , Ltd.
Shiao Rei-tsang
Tetralogic Pharmaceuticals Corporation
LandOfFree
IAP binding compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with IAP binding compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IAP binding compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664374